Merck – EASD-2012 Preview- DPP-IV inhibitors- Gathering evidence to takeaway Market share of Sulphonylurea in primary practice

Date: 2015-07
Pages:2
Price:

“EASD-2012 Preview- DPP-IV inhibitors- Gathering evidence to takeaway Market share of Sulphonylureas in primary practice
Two retrospective database analysis comparing DPP-IV inhibitors vs. Sulphonylureas as a treatment of choice for Type 2 diabetic patients in primary care practices (Germany, France, UK- ~n=50,000) are worth mentioning from the posted abstract for EASD-2012 (European Association for the study of Diabetes- October 1st-5th). Both these studies demonstrated favorable benefits of using DPP-IV inhibitors. 1) Lower discontinuation after two years of use with DPP-IV inhibitors in the primary care setting vs. sulphonylurea (Patients remain on treatment with DPP-IV class 61% vs. 51% with sulphonylureas) and
2) Better CV outcome with DPP-IV inhibitors vs. Sulphonylurea (25% lower macrovascular events with DPP-IV inhibitors vs. sulphonylureas).”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample